Loading...
XNAS
SRPT
Market cap1.90bUSD
Jul 09, Last price  
19.37USD
1D
1.79%
1Q
-61.50%
Jan 2017
-29.38%
Name

Sarepta Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:SRPT chart
P/E
8.09
P/S
1.00
EPS
2.39
Div Yield, %
—
Shrs. gr., 5y
7.94%
Rev. gr., 5y
37.94%
Revenues
1.90b
+52.97%
4,783,760115,29110,985,19121,258,15517,585,00029,420,00046,990,00037,329,00014,219,0009,757,0001,253,0005,421,000154,584,000301,034,000380,833,000540,099,000701,887,000933,013,0001,243,336,0001,901,979,000
Net income
235m
P
-16,675,864-31,073,012-27,167,725-23,952,625-25,159,000-32,177,000-2,318,000-121,287,000-111,985,000-135,789,000-220,030,000-267,265,000-50,688,000-361,918,000-715,075,000-554,128,000-418,780,000-703,488,000-535,977,000235,239,000
CFO
-206m
L-58.92%
-14,668,967-20,613,369-24,677,155-12,339,313-8,800,000-15,209,000-23,679,000-29,694,000-64,695,000-128,539,000-149,465,000-245,820,000-231,996,000-388,660,000-456,463,000107,466,000-443,172,000-325,346,000-500,993,000-205,787,000
Earnings
Aug 05, 2025

Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
URL
https://www.sarepta.com/
IPO date
Jun 04, 1997
Employees
1,162
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,901,979
52.97%
1,243,336
33.26%
933,013
32.93%
Cost of revenue
1,681,493
1,509,601
1,483,100
Unusual Expense (Income)
NOPBT
220,486
(266,265)
(550,087)
NOPBT Margin
11.59%
Operating Taxes
25,535
15,879
13,525
Tax Rate
11.58%
NOPAT
194,951
(282,144)
(563,612)
Net income
235,239
-143.89%
(535,977)
-23.81%
(703,488)
67.99%
Dividends
Dividend yield
Proceeds from repurchase of equity
105,757
51,246
30,043
BB yield
-0.81%
-0.58%
-0.26%
Debt
Debt current
141,173
15,489
Long-term debt
1,522,070
1,432,290
1,674,937
Deferred revenue
437,000
485,000
Other long-term liabilities
374,150
41,100
36,942
Net debt
34,115
(109,314)
(330,269)
Cash flow
Cash from operating activities
(205,787)
(500,993)
(325,346)
CAPEX
(136,956)
(76,106)
(30,824)
Cash from investing activities
755,561
(165,803)
(1,046,883)
Cash from financing activities
124,806
125,004
232,507
FCF
(536,606)
(798,620)
(388,961)
Balance
Cash
1,354,792
1,676,250
1,989,374
Long term investments
133,163
6,527
31,321
Excess cash
1,392,856
1,620,610
1,974,044
Stockholders' equity
(4,211,182)
(4,445,286)
(3,911,891)
Invested Capital
7,442,671
7,197,376
6,423,621
ROIC
2.66%
ROCE
6.82%
EV
Common stock shares outstanding
107,875
92,398
87,559
Price
121.59
26.09%
96.43
-25.58%
129.58
43.90%
Market cap
13,116,521
47.21%
8,909,939
-21.47%
11,345,895
55.05%
EV
13,150,636
8,800,625
11,015,626
EBITDA
258,210
(221,868)
(508,223)
EV/EBITDA
50.93
Interest
18,391
22,010
53,248
Interest/NOPBT
8.34%